Efficacy and Safety of Cladribine in Combination With CAG in Newly Diagnosed Unfit Patients With AML

Acute Myeloid Leukemia Clinical Trial

Official title:

Efficacy and Safety of Cladribine in Combination With G-CSF,Low-dose Cytarabine and Aclarubicin in Newly Diagnosed Unfit Patients With Acute Myeloid Leukemia

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT04254640
• Other study ID #: AML-2020
• Status: Not yet recruiting
• Phase: Phase 2
• Start date: March 1, 2021
• Est. completion date: December 31, 2023

Study information

• Verified date: January 2020
• Source: Sun Yat-sen University
• Contact: wang hua, MD.
• Phone: 0086-02087342462
• Email: wanghua[@]sysucc.org.cn
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

In this study, the investigators conducted a phase II trial that evaluated the efficacy and safety of cladribine in combination with modified CAG regimen (low-dose cytarabine and aclarubicin) in elderly patients with AML.

Description:

The low-intensity chemotherapy were developed to reduce the early mortality and improve the benefit-risk ratio for longterm survival in elderly or unfit AML patients.Previous studies revealed that the standard dose of CAG regimen consisting of low-dose cytarabine and aclarubicin in combination with granulocyte colonystimulating factor (G-CSF) priming as an induction therapy was well-tolerated by patients and led to a complete remission (CR) rate of 50.0% in patients aged≥ 70 years. Cladribine (2-chlorodeoxyadenosine ) is a nucleoside analogue of anti-adenosine deaminase that has extensive antitumor activity in hematological tumor.The purine analog 2-CdA increases the uptake of Ara-C and the accumulation of its active cytotoxic metabolite 5α-triphosphate Ara-C (Ara-CTP) in leukemia cells. This finding suggests that synergy occurs between cladribine and cytarabine. In this study, the investigators conducted a phase II trial that evaluated the efficacy and safety of cladribine in combination with modified CAG regimen (low-dose cytarabine and aclarubicin) in unfit patients with AML.Patients will receive C-CAG regimen as follows: cladribine 5 mg/m2, d1-5; G-CSF 300 µg, d0-9; aclarubicin 10 mg, d3-6; cytarabine 10mg/ m2 q12h, SC, d3-9; 4 weeks per cycle. The participants are permitted to quit the study if complete remission (CR) was not achieved after two courses of chemotherapy.The participants will be treated for a total of six cycles unless disease progression or unacceptable side effects are observed or participants withdrew their consent.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 34
• Est. completion date: December 31, 2023
• Est. primary completion date: June 1, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 90 Years

Eligibility

Inclusion Criteria:

Patients with:

1. a diagnosis of AML according to WHO 2016 classification (excluding acute promyelocytic leukemia) including secondary AML (after an antecedent hematological disease (e.g. MDS) and therapy-related AML

2. Patients 60 years and older.

3. Patients NOT eligible for standard chemotherapy, defined as hematopoietic cell transplantation comorbidity index (HCT-CI) = 3 or Patients NOT eligible for standard chemotherapy for other reasons (wish of patient).

4. White blood cell (WBC) = 10 x109/L (prior hydroxyurea allowed for a maximum of 5 days, stop 2 days before start cladribine treatment)

5. Adequate renal and hepatic functions unless clearly disease related as indicated by the following laboratory values:

• Serum creatinine = 221.7 µmol/L (= 2.5 mg/dL ), unless considered AML-related -Serum bilirubin = 2.5 x upper limit of normal (ULN), unless considered AML-

• related or due to Gilbert's syndrome

• Alanine transaminase (ALT) = 2.5 x ULN, unless considered AML-related

6. WHO performance status 0, 1 or 2.

7. Patient is willing and able to use adequate contraception during and until 5 months after the last protocol treatment.

8. Written informed consent.

9. Patient is capable of giving informed consent.

Exclusion Criteria:

1. Acute promyelocytic leukemia.

2. Acute leukemia's of ambiguous lineage according to WHO 2016

3. Patient has symptomatic central nervous system (CNS) leukemia (NO routinely lumbar puncture required to investigate CNS involvement)

4. Blast crisis of chronic myeloid leukemia.

5. Diagnosis of any previous or concomitant malignancy is an exclusion criterion:

6. except when the patient completed successfully treatment (chemotherapy and/or surgery and/or radiotherapy) with curative intent for this malignancy at least 6 months prior to randomization. OR

7. except for basal and squamous cell carcinoma of the skin or in situ carcinoma of the cervix

8. Patients previously treated for AML (any antileukemic therapy including investigational agents), a short treatment period ( = 5 days) with Hydroxyurea is allowed

9. Current concomitant chemotherapy, radiation therapy, or immunotherapy; other than hydroxyurea

10. Concurrent severe and/or uncontrolled medical condition (e.g. uncontrolled diabetes, infection, hypertension, pulmonary disease etc.)

11. Cardiac dysfunction as defined by:

• Myocardial infarction within the last 3 months of study entry, or

• Reduced left ventricular function with an ejection fraction < 40% as measured by MUGA scan or echocardiogram or

• Unstable angina or

• New York Heart Association grade IV congestive heart failure or

• Unstable cardiac arrhythmias.

12. History of stroke or intracranial hemorrhage within 6 months prior to randomization.

13. Patient has a history of human immunodeficiency virus or active infection with Hepatitis C or B.

14. Patients known to be pregnant

15. Patients with a history of non-compliance to medical regimens or who are considered unreliable with respect to compliance.

16. Patients with any serious concomitant medical condition which could, in the opinion of the investigator, compromise participation in the study.

17. Patients who have senile dementia, mental impairment or any other psychiatric disorder that prohibits the patient from understanding and giving informed consent.

18. Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule

Related Conditions & MeSH terms

• Acute Myeloid Leukemia
• Elderly Patients
• Leukemia
• Leukemia, Myeloid
• Leukemia, Myeloid, Acute
• Newly Diagnosed

Intervention

Drug:
• Cladribine Injection
Cladribine 5 mg/m2, intravenous drip,d1-5,4 weeks per cycle.
• Aclarubicin
aclarubicin 10 mg, intravenous drip,d3-6,4 weeks per cycle.
• G-CSF
G-CSF 300 µg,subcutaneous injection, d0-9,4 weeks per cycle.
• cytarabine
cytarabine 10mg/ m2, subcutaneous injectionq,q12h, d3-9,4 weeks per cycle.

Locations

Country	Name	City	State
China	Sun Yat-sen University Cancer Center	Guangzhou	Guangdong

Sponsors (1)

Lead Sponsor	Collaborator
Sun Yat-sen University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Cumulative Complete Remission (CR) / CR with incomplete blood count (CRi) rate	Cumulative CR/CRi rate during 2 cycles	At the end of Cycle 2 (each cycle is 28 days)
Secondary	Safety and tolerability of Cladribine in Combination With CAG determined by the type, frequency, severity and relationship of adverse events to study treatment	Safety and tolerability of Cladribine in Combination With treatment for CAG for AML (type, frequency, severity and relationship of adverse events to study treatment).	1 years
Secondary	Event free survival (EFS)	The time from registration to induction failure, death or relapse whichever occurs first	5 years
Secondary	Overall survival (OS)	The time from the date of registration to the date of death, whatever the cause. Patients still alive at the date last contact will be censored.	5 years
Secondary	Prognostic value of MRD	Assessment of the prognostic value of Minimal Residual Disease (MRD) by flowcytometry or PCR	9 months and at relapse